By Kelly Cloonan
Johnson & Johnson is scheduled to report its first-quarter results before the market opens on Tuesday. Here is what you need to know.
NET INCOME: The drug and medical-device maker is expected to post a profit of $6.11 billion, or $2.50 a share, compared with $11 billion, or $4.54 a share, the year before, according to FactSet.
ADJUSTED EARNINGS: Stripping out certain one-time items, earnings are expected to come in at $2.68 a share, compared with $2.77 a share the prior year.
REVENUE: The company is expected to report $23.61 billion in sales, compared with $21.89 billion in the year-ago quarter, according to FactSet.
The stock has risen 11% during the past three months and recently traded around $236.11.
WHAT TO WATCH:
--Analysts at BofA Securities expect J&J to post higher sales, driven by growth in both its pharmaceutical and medical-device businesses. The analysts project J&J's cancer drug Darzalex, immunology treatment Tremfya and central nervous system portfolio will power its pharma results.
--Declining sales for Stelara, a treatment for skin and stomach conditions, are expected to cause a more moderate hit to J&J's results going forward. Last year J&J lost patent protection for Stelara, which has been one of its best-selling drugs, allowing competitors to introduce a number of lower-cost versions. Citi analysts said the company's 2026 guidance assumes that the Stelara erosion curve moderates after accelerating in the second half of last year, with sales for the drug plunging nearly 48% in the fourth quarter.
--Earlier this year, J&J reached an agreement with the Trump administration to lower prices for U.S. customers in exchange for an exemption from tariffs. The agreement came on the back of similar drug-pricing deals between the U.S. government and pharmaceutical companies like GSK, Merck and Novartis.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
April 13, 2026 12:44 ET (16:44 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
Comments